Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Sells 10,382 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now owns 148,253 shares of the company’s stock, valued at $1,285,353.51. The trade was a 6.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Stoke Therapeutics Stock Down 2.2 %

NASDAQ:STOK opened at $8.15 on Friday. The business’s 50-day moving average price is $9.47 and its two-hundred day moving average price is $11.42. Stoke Therapeutics, Inc. has a twelve month low of $6.29 and a twelve month high of $17.58. The stock has a market cap of $431.68 million, a P/E ratio of -3.88 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million. On average, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 18th. HC Wainwright reissued a “buy” rating and set a $47.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. Chardan Capital reissued a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics currently has an average rating of “Buy” and an average target price of $23.00.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently modified their holdings of STOK. Toronto Dominion Bank purchased a new position in shares of Stoke Therapeutics during the 4th quarter valued at about $35,001,000. RTW Investments LP raised its holdings in shares of Stoke Therapeutics by 10.1% during the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock valued at $56,512,000 after buying an additional 471,240 shares in the last quarter. Norges Bank purchased a new position in shares of Stoke Therapeutics during the 4th quarter valued at about $3,472,000. Tang Capital Management LLC purchased a new position in shares of Stoke Therapeutics during the 4th quarter valued at about $3,309,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Stoke Therapeutics during the 4th quarter valued at about $3,218,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.